- Kytopen and Bio-Techne announce partnership on an integrated cellular engineering workflow to expedite cell therapy manufacturing.
- The TcBuster™ system offers a fast and scalable method to integrate large, multigene cargos with high editing efficiency in a single vector, while Flowfect® continuous flow technology enables the gentle, high-efficiency processing of billions of cells in minutes.
- The companies' combined technologies deliver high gene insertion efficiencies and high cell viabilities, enabling a non-viral gene-editing workflow ideal for the development of advanced cell therapies.
- The data will be presented in a poster at ISCT, May 7-10, 2025, in New Orleans.
CAMBRIDGE, Mass. and MINNEAPOLIS, May 8, 2025 -- Kytopen Corp., a leader in providing continuous flow cellular engineering technologies and Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative life science research tools today announced a partnership aimed at streamlining gene delivery solutions for the development and manufacture of advanced cell therapies. The collaboration will focus on the synergies developers can achieve by utilizing the TcBuster™ GMP non-viral genome engineering system and the Flowfect Tx™ GMP cellular engineering platform. Together, these technologies offer a clear path to shortened workflows for generating more efficient genome engineering of immune cell therapies, expediting their advancement to clinical stages and subsequent manufacturing.
Non-viral TcBuster offers numerous benefits over traditional lentivirus-based engineering methods. The hyperactive TcBuster transposase enables delivery of multiple genes simultaneously while maintaining high editing efficiency and a de-risked insertional profile. Flowfect® technology is a highly tunable system. It is unique in that it combines mechanical, electrical, and chemical forces, and allows the adjustment of multiple parameters to maximize transfection efficiency, cell health, and cell yield, while continuous flow enables the processing of hundreds of billions of healthy, high-quality engineered cells in just minutes. Together these technologies provide a streamlined gene delivery process that can achieve therapeutic doses quicker.
"We are excited about the opportunity to work with such a reputable life science provider as Bio-Techne", said Kevin Gutshall, Chief Commercial Officer at Kytopen, "Together our technologies offer a non-viral, gene-editing platform suitable for a range of immune cell types, in particular non-dividing cells and those sensitive to apoptosis, that will enable developers to bring more effective, advanced cell therapies to market quicker."
Data generated through the collaboration will be presented at the International Society of Cell & Gene Therapy (ISCT) Annual Meeting, May 7-10, 2025, in New Orleans, USA. The data will also be featured in Kytopen's Global Showcase Oral Presentation on Thursday, May 8, 2025, at 6:00pm. For more information at ISCT, the Kytopen and Bio-techne teams will be available to answer any questions at booths 347 and booth 932, respectively.
ISCT Poster Presentation. Wednesday, May 7, 2025, at 6:00pm; POSTER BOARD: 1105
CONTINUOUS FLOW TRANSFECTION WITH FLOWFECT® TECHNOLOGY AS AN EFFICIENT, NON-VIRAL TECHNOLOGY FOR SCALABLE CRISPR-MEDIATED ENGINEERING OF PRIMARY T CELLS
Global Showcase. 15 min Presentation, Thursday, May 8, 2025, at 6:00pm
A FULLY VALIDATED, NON-VIRAL GMP PLATFORM FOR THE MANUFACTURE OF ENGINEERED CELLS AT CLINICAL AND COMMERCIAL SCALE
For further information:
Kytopen:
Investor
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
